Убиквитин-независимый протеолиз основного белка миелина и его роль в развитии экспериментального аутоиммунного энцефаломиелита (1105762), страница 19
Текст из файла (страница 19)
Prakash, L. Tian, K. S. Ratliff, et al. // Nat Struct Mol Biol. – 2004. – Vol. 11, no. 9. – P. 830837.10038.Recognition of the polyubiquitin proteolytic signal / J. S. Thrower, L. Hoffman, M.Rechsteiner, et al. // EMBO J. – 2000. – Vol. 19, no. 1. – P. 94-102.39.Regulation of Pax3 by proteasomal degradation of monoubiquitinated protein in skeletalmuscle progenitors / S. C. Boutet, M. H. Disatnik, L. S. Chan, et al. // Cell. – 2007. – Vol. 130,no. 2. – P.
349-362.40.Modification by single ubiquitin moieties rather than polyubiquitination is sufficient forproteasomal processing of the p105 NF-kappaB precursor / Y. Kravtsova-Ivantsiv, S. Cohen andA. Ciechanover // Mol Cell. – 2009. – Vol. 33, no.
4. – P. 496-504.41.The size of the proteasomal substrate determines whether its degradation will bemediated by mono- or polyubiquitylation / N. Shabek, Y. Herman-Bachinsky, S. Buchsbaum, etal. // Mol Cell. – 2012. – Vol. 48, no. 1. – P. 87-97.42.Proteasome substrate degradation requires association plus extended peptide / J.Takeuchi, H. Chen and P.
Coffino // EMBO J. – 2007. – Vol. 26, no. 1. – P. 123-131.43.Susceptibility of p53 unstructured N terminus to 20 S proteasomal degradation programsthe stress response / P. Tsvetkov, N. Reuven, C. Prives, et al. // J Biol Chem. – 2009. – Vol. 284,no. 39. – P. 26234-26242.44.The nanny model for IDPs / P. Tsvetkov, N. Reuven and Y. Shaul // Nat Chem Biol. –2009. – Vol. 5, no. 11.
– P. 778-781.45.The caspase-like sites of proteasomes, their substrate specificity, new inhibitors andsubstrates, and allosteric interactions with the trypsin-like sites / A. F. Kisselev, M. GarciaCalvo, H. S. Overkleeft, et al. // J Biol Chem. – 2003. – Vol. 278, no. 38. – P. 35869-35877.46.Nature of pharmacophore influences active site specificity of proteasome inhibitors / M.Screen, M. Britton, S. L. Downey, et al. // J Biol Chem. – 2010. – Vol. 285, no. 51. – P. 4012540134.47.Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsinlike activity of the proteasome / F.
Parlati, S. J. Lee, M. Aujay, et al. // Blood. – 2009. – Vol.114, no. 16. – P. 3439-3447.48.Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells /L. R. Dick, A. A. Cruikshank, A. T. Destree, et al. // J Biol Chem. – 1997. – Vol. 272, no. 1. – P.182-188.49.How an inhibitor of the HIV-I protease modulates proteasome activity / G. Schmidtke, H.G. Holzhutter, M. Bogyo, et al. // J Biol Chem. – 1999. – Vol. 274, no. 50. – P. 35734-35740.10150.Molecular basis for proline- and arginine-rich peptide inhibition of proteasome / A.Anbanandam, D. C.
Albarado, D. C. Tirziu, et al. // J Mol Biol. – 2008. – Vol. 384, no. 1. – P.219-227.51.Targeted inhibition of the immunoproteasome is a potent strategy against models ofmultiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasomeinhibitors / D. J.
Kuhn, S. A. Hunsucker, Q. Chen, et al. // Blood. – 2009. – Vol. 113, no. 19. – P.4667-4676.52.Lack of proteasome active site allostery as revealed by subunit-specific inhibitors / J.Myung, K. B. Kim, K. Lindsten, et al. // Mol Cell. – 2001. – Vol. 7, no. 2. – P. 411-420.53.A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokineproduction and attenuates progression of experimental arthritis / T.
Muchamuel, M. Basler, M.A. Aujay, et al. // Nat Med. – 2009. – Vol. 15, no. 7. – P. 781-787.54.Inhibitors of the immunoproteasome: current status and future directions / Z. Miller, L.Ao, K. B. Kim, et al. // Curr Pharm Des. – 2013. – Vol. 19, no. 22. – P. 4140-4151.55.Selective immunoproteasome inhibitors with non-peptide scaffolds identified fromstructure-based virtual screening / V. Kasam, N. R. Lee, K.
B. Kim, et al. // Bioorg Med ChemLett. – 2014. – Vol. 24, no. 15. – P. 3614-3617.56.Generation, translocation, and presentation of MHC class I-restricted peptides / M. T.Heemels and H. Ploegh // Annu Rev Biochem. – 1995. – Vol. 64, no. – P. 463-491.57.Survival of the fitters / H. G. Rammensee // Nature. – 2002. – Vol. 419, no. 6906. – P.443-445.58.Cell biology of antigen processing in vitro and in vivo / E. S. Trombetta and I. Mellman //Annu Rev Immunol. – 2005.
– Vol. 23, no. – P. 975-1028.59.Towards a systems understanding of MHC class I and MHC class II antigen presentation/ J. Neefjes, M. L. Jongsma, P. Paul, et al. // Nat Rev Immunol. – 2011. – Vol. 11, no. 12. – P.823-836.60.ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum /T. Serwold, F. Gonzalez, J. Kim, et al. // Nature.
– 2002. – Vol. 419, no. 6906. – P. 480-483.61.Beyond the proteasome: trimming, degradation and generation of MHC class I ligands byauxiliary proteases / L. Saveanu, D. Fruci and P. van Endert // Mol Immunol. – 2002. – Vol. 39,no. 3-4. – P. 203-215.62.A recyclable assay to analyze the NH(2)-terminal trimming of antigenic peptideprecursors / L. Burri, C. Servis, L.
Chapatte, et al. // Protein Expr Purif. – 2002. – Vol. 26, no. 1.– P. 19-27.10263.An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope /U. Seifert, C. Maranon, A. Shmueli, et al. // Nat Immunol. – 2003. – Vol. 4, no. 4. – P. 375-379.64.An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHCclass I-presented peptides / T. Saric, S. C. Chang, A. Hattori, et al. // Nat Immunol. – 2002.
–Vol. 3, no. 12. – P. 1169-1176.65.A cytosolic pathway for MHC class II-restricted antigen processing that is proteasomeand TAP dependent / M. K. Tewari, G. Sinnathamby, D. Rajagopal, et al. // Nat Immunol. –2005. – Vol. 6, no. 3. – P. 287-294.66.Control of dendritic cell cross-presentation by the major histocompatibility complex classI cytoplasmic domain / G. Lizee, G.
Basha, J. Tiong, et al. // Nat Immunol. – 2003. – Vol. 4, no.11. – P. 1065-1073.67.И. А. З. Е.И.Гусев, А.Н.Бойко (2004). Рассеянный склероз и другиедемиелинизирующие заболевания. Москва, Миклош.68.Immunology of multiple sclerosis / M. Sospedra and R. Martin // Annu Rev Immunol. –2005. – Vol. 23, no. – P. 683-747.69.Multiple sclerosis etiology: beyond genes and environment / R. Mechelli, V. Annibali, G.Ristori, et al. // Expert Rev Clin Immunol. – 2010.
– Vol. 6, no. 3. – P. 481-490.70.Blood-brain barrier changes and cell invasion differ between therapeutic immuneclearance of neurotrophic virus and CNS autoimmunity / M. J. Fabis, T. W. Phares, R. B. Kean,et al. // Proc Natl Acad Sci U S A. – 2008. – Vol. 105, no. 40. – P. 15511-15516.71.Regulation of lymphocyte traffic by adhesion molecules / M. Fabbri, E. Bianchi, L.Fumagalli, et al. // Inflamm Res. – 1999. – Vol. 48, no. 5. – P. 239-246.72.Expression of specific chemokines and chemokine receptors in the central nervoussystem of multiple sclerosis patients / T.
L. Sorensen, M. Tani, J. Jensen, et al. // J Clin Invest. –1999. – Vol. 103, no. 6. – P. 807-815.73.Matrix metalloproteinases in the normal human central nervous system, microglialnodules, and multiple sclerosis lesions / A. Maeda and R. A. Sobel // J Neuropathol Exp Neurol.– 1996.
– Vol. 55, no. 3. – P. 300-309.74.In vivo imaging of partially reversible th17 cell-induced neuronal dysfunction in thecourse of encephalomyelitis / V. Siffrin, H. Radbruch, R. Glumm, et al. // Immunity. – 2010. –Vol. 33, no. 3. – P. 424-436.10375.A reversible form of axon damage in experimental autoimmune encephalomyelitis andmultiple sclerosis / I. Nikic, D. Merkler, C.
Sorbara, et al. // Nat Med. – 2011. – Vol. 17, no. 4. –P. 495-499.76.EAE: imperfect but useful models of multiple sclerosis / B. A. t Hart, B. Gran and R.Weissert // Trends Mol Med. – 2011. – Vol. 17, no. 3. – P. 119-125.77.Endogenous presentation of self myelin epitopes by CNS-resident APCs in Theiler'svirus-infected mice / Y. Katz-Levy, K. L.
Neville, A. M. Girvin, et al. // J Clin Invest. – 1999. –Vol. 104, no. 5. – P. 599-610.78.T-cell recognition of an immunodominant myelin basic protein epitope in multiplesclerosis / K. Ota, M. Matsui, E. L. Milford, et al. // Nature. – 1990. – Vol. 346, no.
6280. – P.183-187.79.Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis/ R. Martin and H. F. McFarland // Crit Rev Clin Lab Sci. – 1995. – Vol. 32, no. 2. – P. 121-182.80.Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiplesclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction / H.Babbe, A.
Roers, A. Waisman, et al. // J Exp Med. – 2000. – Vol. 192, no. 3. – P. 393-404.81.Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitroactivation of lymph node cells by myelin basic protein: requirement for Lyt 1+ 2- T lymphocytes/ C. B. Pettinelli and D. E. McFarlin // J Immunol. – 1981. – Vol. 127, no. 4. – P.
1420-1423.82.W. Paul (2003). Fundamental immunology. Philadelphia, Lippincott Williams & Wilkins83.Selection for T-cell receptor V beta-D beta-J beta gene rearrangements with specificityfor a myelin basic protein peptide in brain lesions of multiple sclerosis / J. R.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
